-
New research identifies a link between diabetes medications and multiple sclerosis
Time of Update: 2023-01-05
Age and sex differences on anti-hyperglycemic medication exposure and risk of newly diagnosed multiple sclerosis in propensity score matched type 2 diabetics A new study has found that antihyperglycemic drugs used to treat type 2 diabetes increase the risk of multiple sclerosis in people over the age of 45, especially women.
-
Two articles prove that a new drug can fight both COVID and cancer
Time of Update: 2022-12-30
”The role of GRP78 in virus transmissionIn search of a more stable way to fight COVID-19, Lee and her colleagues at the Keck School of Medicine at USC and the Cleveland Clinic Florida Research and Innovation Center set out to study the role of GRP78, a key cell chaperone protein that helps regulate the folding of other cellular proteins.
-
The 7th batch of drug collection, 14 provinces landing summary (collection
Time of Update: 2022-11-01
At present, each province has successively issued notices on the implementation of the seventh batch of national procurement, which is summarized as follows: The Joint Procurement Office previously informed that the results of the seventh batch of national procurement will be implemented in November 2022, and the specific implementation date will be subject to the notice issued by various places.
-
Suspected of illegally using patents to hinder competition, Novartis was again investigated by "surprise
Time of Update: 2022-10-01
Novartis Corporation Statement Novartis Corporation Statement ▲The screenshot is from the official website of Novartis Specifically, COMCO said there was news that the pharmaceutical company was trying to initiate litigation by using a patent to protect its drugs for skin diseases from competing products.
-
The study found that the biochemical reagent α-ketoglutarate can prolong life
Time of Update: 2022-07-04
The researchers also found that mice fed alpha-ketoglutarate showed decreased levels of systemic inflammatory cytokines .
The discovery of the function of α-ketoglutarate is of great significance to human anti-aging research .
-
"14th Five-Year" Chinese Medicine Development Plan released
Time of Update: 2022-04-28
"14th Five-Year" development goals:"14th Five-Year" development goals: By 2025, the health service capacity of traditional Chinese medicine will be significantly enhanced, the high-quality development policy and system of traditional Chinese medicine will be further improved, the revitalization and development of traditional Chinese medicine will achieve positive results, and the unique advantages in the construction of a healthy China will be fully utilized .
-
Good news for breast cancer patients
Time of Update: 2022-04-23
Trastuzumab, Emmett, constantly explores the cure and survival of breast cancer patients. Using medical evidence to provide a strong backing for clinical diagnosis and treatment of early breast cance
-
Gastroenterology: Lower serological responses to COVID-19 mRNA vaccine in patients with inflammatory bowel disease treated with anti-TNFα
Time of Update: 2022-03-05
Figure: Schematic representation of anti-TNFα treatment in patients with inflammatory bowel disease In this prospective study of IBD patients stratified by treatment, all patients had a serological response to 2 doses of BNT162b2; however, in patients receiving anti-TNFα therapy, regardless of timing of administration and drug level, Its magnitude is significantly reduced .
-
New Strategies to Fight Viral Infections
Time of Update: 2022-02-16
Their experiments showed that inhibiting various components of a network of proteins known as mechanistic targets of the rapamycin (mTOR) pathway could prevent RSV from replicating in human cells .
Since some of the drugs shown in this study that inhibit mTOR components and block viral replication are already approved by the U.
-
In 2023, my country’s cardiovascular and cerebrovascular disease drug market will exceed 280 billion yuan
Time of Update: 2022-01-02
In the "Healthy China Action (2019-2030)", specific instructions were made on the prevention and treatment of cardiovascular and cerebrovascular diseases, and it was clearly necessary to promote the "three highs" co-management to carry out overweight and obesity, increased blood pressure and blood sugar, and dyslipidemia and other high-risk groups.
-
Shiyao Forces 14 Class 1 New Drugs Intensive Attack This Year
Time of Update: 2021-12-09
Author: Jun Chen Zuo ShiOn October 26, CSPC Zhongqi Pharmaceutical's clinical application for SYHX2001 tablets submitted as a new drug category 1 was accepted by the CDE, and the product was declared for clinical use in China for the first time .
-
[FDA] The first C5aR inhibitor comes out
Time of Update: 2021-11-14
S. FDA announced the approval of ChemoCentryx's oral selective complement 5a receptor (C5aR) inhibitor Tavneos (avacopan) to be marketed, combined with standard therapies to treat severely active antineutrophil cytoplasmic autoantibodies (ANCA) ) Related vasculitis, including granulomatous polyangiitis (GPA) and microscopic polyangiitis (MPA) .
-
Becco Group has successfully developed a chromium-free primer product series, which will be officially launched at the end of this year
Time of Update: 2021-11-12
After more than 20 years of research and development, Becco's coils have accumulated rich and thin, and successfully developed the BeckryPrim chromium-free primer product series to empower the green development of the industry with environmental protection technology and help build a green China .
-
Express for the treatment of Alzheimer's disease, Genentech's anti-amyloid antibody therapy was approved by the FDA as a breakthrough therapy
Time of Update: 2021-10-22
▎The content team editor of WuXi AppTec today, Genentech, a subsidiary of Roche, announced that the US FDA has granted an anti-β-amyloid antibody therapy gantenerumab breakthrough therapy designation for the treatment of Alzheimer’s disease (AD ) .
-
2 Qilu Class 1 biological drugs are coming
Time of Update: 2021-10-10
On September 28, CDE's official website showed that Qilu Pharmaceutical's QLF32004 and QLP31907 injections for class 1 biological drug injections have obtained the implied license of clinical trials and are intended to be used for the treatment of advanced malignant solid tumors and B-cell malignant tumors .
